TCRαβ+ T cell and CD19+ B cell depletion (TCRαβ/CD19 depletion)

TCRαβ+ T cell and CD19+ B cell depletion is an ex vivo graft engineering technique used primarily in allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host disease (GvHD) and post-transplant lymphoproliferative disorders (Maschan et al., 2016, Blood). This method utilizes immunomagnetic separation technology, such as the CliniMACS system, to selectively remove TCRαβ+ T cells, which are the primary mediators of GvHD, and CD19+ B cells, which can harbor Epstein-Barr virus (EBV) (Bertaina et al., 2014, Blood). Unlike traditional pan-T-cell depletion, this approach preserves TCRγδ+ T cells and natural killer (NK) cells within the graft. These preserved cell populations provide essential anti-infective immunity and maintain a graft-versus-leukemia (GvL) effect, which helps prevent disease relapse (Lang et al., 2015, Bone Marrow Transplantation). The procedure is particularly valuable in haploidentical (half-matched) transplant settings where the risk of GvHD is otherwise high. By reducing the need for intensive post-transplant pharmacological immunosuppression, it aims to improve patient outcomes and accelerate functional immune reconstitution (Miltenyi Biotec, CliniMACS System).

Other names

Alpha/beta T-cell and B-cell depletionTCR alpha/beta and CD19 depletionSelective graft engineeringEx vivo TCRαβ+/CD19+ depletion

Ex vivo immunomagnetic depletion of specific lymphocyte subsets from a hematopoietic stem cell graft using monoclonal antibodies conjugated to paramagnetic beads.